The antihypertensive effect and safety of fosinopril and hydrochlorothiazide combined were compared with each drug singly and placebo in a controlled manner. After a 4-to 5-week placebo lead-in period, 67 mild to moderate essential hypertensive patients (seated diastolic blood pressure £95 and £110 mm Hg) were randomized in a double-blind fashion into four parallel treatment groups: 20 mg fosinopril plus 12.5 mg hydrochlorothiazide, 20 mg fosinopril, 12.5 mg hydrochlorothiazide, and placebo during 8 weeks. Patients were seen biweekly. Sitting diastolic blood pressure was the outcome variable defining therapeutic response. The efficacy of fosinopril plus hydrochlorothiazide as a combined therapy was superior to any single drug (P<.05) and placebo (P<.01) in the treatment of mild to moderate essential hypertension. Mean adjusted systolic/diastolic blood pressure decrements at week 8 were -18.8 /-13.7, -12.9/-11.8, -8.5/-9.3, and -2.11-6.9 mm Hg for the fosinopril plus hydrochlorothiazide, fosinopril, hydrochlorothiazide, and placebo groups, respectively. Clinical adverse events and laboratory changes documented throughout the study were similar to placebo and were mild in severity in all groups. 1 Being a prodrug, fosinopril needs to be hydroryzed into fosinoprilat, the active form, at the liver and, while absorbed, at the intestinal mucosa. It is 95% to 99% protein bound in the systemic circulation. Elimination is evenly divided between hepatic and renal routes, 2 a favorable pattern when diseases of either organ exist. 34 Fosinopril has been administered in doses ranging from 10 to 40 mg once daily. 5 Hydrochlorothiazide, a widely used antihypertensive thiazide diuretic, enhances sodium and chloride excretion. Its diuretic effect is associated with moderate potassium and bicarbonate losses, lipid and carbohydrate metabolism alterations, and hyperuricemia.
A ngiotensin converting enzyme (ACE) inhibitors /\ are widely used in the treatment of hyperten-J. A-sion because of their efficacy and convenient safety profile. Fosinopril, a phosphinic acid derivative, is a member of a new class of ACE inhibitors with long-lasting action, allowing once-dairy dosing. 1 Being a prodrug, fosinopril needs to be hydroryzed into fosinoprilat, the active form, at the liver and, while absorbed, at the intestinal mucosa. It is 95% to 99% protein bound in the systemic circulation. Elimination is evenly divided between hepatic and renal routes, 2 a favorable pattern when diseases of either organ exist. 34 Fosinopril has been administered in doses ranging from 10 to 40 mg once daily. 5 Hydrochlorothiazide, a widely used antihypertensive thiazide diuretic, enhances sodium and chloride excretion. Its diuretic effect is associated with moderate potassium and bicarbonate losses, lipid and carbohydrate metabolism alterations, and hyperuricemia.
Combining an ACE inhibitor and diuretic is common in clinical practice because of their additive antihypertensive effects. When antihypertensive agents with different mechanisms of action are given in combination, in many patients the effective dose of each is smaller than the effective dose of each agent if given alone; the lower doses minimize the potential for dose-dependent adverse events. 6 Furthermore, ACE inhibitors may blunt some of the adverse metabolic effects of thiazides, including hypokalemia. 7 ' 8 From Gfnica de Hipertensi6n Arterial, Institute) Nacional de la Nutrickin "Salvador Zubiran" (M.F., J.A.); Clfnica de Hipertensi6n Arterial, Hospital de Cardiologfa "Luis M6ndez," Centra Medico Nacional Siglo XXI, IMSS (P.C., J.V.); and Bristol-Myers Squibb Pharmaceutical Research Institute (R.M., D.G.), Mexico City, Mexico.
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The purpose of the present study was to compare the safety and efficacy of the aggregate, once-daily administration of 20 mg fosinopril plus 12.5 mg hydrochlorothiazide against each drug singly and placebo in the treatment of patients with mild to moderate essential hypertension.
Methods
Men and nonpregnant, nonlactating women 18 to 75 years of age with mild to moderate essential hypertension (defined as seated diastolic blood pressure [SeDBP] 2:95 and £110 mmHg) at two major referral centers in Mexico City were candidates for the study. Patient recruitment started after observers were trained and standardized at each center, and a written consent was obtained from each patient. Exclusion criteria were recent acute myocardial infarction; angina pectoris; cerebrovascular or neurological disease; congestive heart failure; renal, hepatic, or collagen vascular disease; and known allergies or hypersensiuvity to any ACE inhibitors, diuretics, or sulfa-containing medications. Permitted concomitant medications included hypogrycemic agents, antibiotics, acetaminophen, and any other chronically administered drugs with minimal or no effect on blood pressure. Aspirin and nonsteroidal antiinflammatory drugs were not permitted. Dietary salt restriction was advised. Women with childbearing potential required a negative pregnancy test at entry to the study and were instructed to use an effective contraceptive method during their trial participation.
Patients were randomized in a double-blind, placebo-controlled fashion in four parallel groups: the combination of 20 mg fosinopril plus 12.5 mg hydrochlorothiazide, 20 mg fosinopril, 12.5 mg hydrochlorothiazide, and placebo, all administered once dairy for the treatment of mild to moderate essential hypertension. Fosinopril plus hydrochlorothiazide combination therapy consisted of individual distinct tablets of each drug.
The study design included an initial single-blind placebo lead-in period (period A) with visits at 0, 3, 4, and optional 5 weeks. Patients in period A were eligible for randomization to active drug treatment if they had three blood pressure deter- minations averaging SeDBP £95 and £110 mmHg in two consecutive visits 1 week apart; others were excluded from the study. Those continuing to period B received randomized double-blind, placebo-controlled treatment for 8 weeks. The measure of efficacy was based on the changes from baseline SeDBP compared among the four treatment groups at 0, 2, 4, 6, and 8 weeks of treatment.
Initial complete medical history and physical examination were done; thereafter, medical history and physical exams were performed at each subsequent visit. Laboratory testing, including hematology and chemistry profiles (glucose, blood urea nitrogen, creatinine, uric acid, calcium, phosphorous, total proteins, albumin, cholesterol, lactic dehydrogenase, alanine aminotransferase, aspartate aminotransferase, sodium, potassium, chloride) and urinah/sis, was done at baseline and during treatment at weeks 4 and 8.
Electrocardiograms were obtained at baseline and the end of the study. Each blood pressure determination was recorded as Korotkoff phase I and V sounds for systolic and diastolic values, respectively, using a mercury sphygmomanometer. These determinations were made 24±3 hours after the previous morning dose of the assigned medication. Blood pressure values were reported as the mean of three consecutive determinations after the patients were sitting for at least 5 minutes; the same arm and equipment were used, and conditions were constant from visit to visit. Compliance with drug treatment was determined by medication count. Efficacy was established based on changes from the baseline SeDBP during the active treatment period, considering either normalization of blood pressure at 90 mm Hg or lower or responders if they had a 10% or higher decrement from baseline. Clinical adverse events were evaluated and their characteristics recorded as spontaneously referred to by the patient. Laboratory abnormalities were identified and monitored until values returned to normal or remained stable. The double-blind procedure was not tested at the end of the study.
For statistical analysis the x 2 test or analysis of variance was used to test homogeneity of treatment groups. The base efficacy variable was SeDBP. Comparisons among treatment groups were made with the use of linear models to define changes after treatment as a function of the baseline value. Statistical significance was considered at a value of P<.05.
Results
Sixty-seven mestizo patients, 23 men and 44 women, were randomized and analyzed in the intent-to-treat population, defined as those patients having blood pressure data at baseline and at least one follow-up visit. Mean age ranged from 48 to 56 years. When age was categorized into three regular intervals, each one containing one third of the patients per group, youngest patients were found in the fosinopril group and older in the hydrochlorothiazide group. All patients but one from the hydrochlorothiazide group were under previous antihypertensive treatment, consisting mainly of a diuretic, an ACE inhibitor, or a combination of both.
No statistically significant differences between treatment groups were found for SeDBP and seated systolic blood pressure (SeSBP), heart rate, end-organ damage, and general demographic data at baseline (Table 1) . SeSBP was normalized only in the fosinopril groups as early as the second week with the combination of 20 mg fosinopril plus 12.5 mg hydrochlorothiazide and at 8 weeks with monotherapy. Both fosinopril regimens at the end of therapy had higher normalization rates (P<.05) than either hydrochlorothiazide or placebo. Decrements in SeDBP among the groups and their statistical significance are shown in Table 2 . Patient compliance, as assessed by pill counting at each visit, was similar for each group. After 8 weeks of treatment, the frequency of favorable responses was higher in the fosinopril plus hydrochlorothiazide group (Table 2) . 
Safety
Adverse events, defined as those clinical symptoms or signs that appeared or increased in severity, were documented throughout the study regardless of their possible causal relation with the administered therapeutic modality. The frequency of spontaneous reported adverse events for the fosinopril plus hydrochlorothiazide group was 6 of 17 (35.3%), 9 of 16 (56.2%) for fosinopril monotherapy, 5 of 17 (29.4%) for hydrochlorothiazide therapy, and 10 of 17 (58.8%) for those receiving placebo. None of these events were serious and resolved spontaneously during therapy or as soon as it was discontinued (Table 3) . At 6 weeks of therapy two patients were withdrawn from the study. One of them, receiving fosinopril, reported an acute gout attack precipitated by alcoholic beverage consumption, and the other, taking placebo, reported the persistence of dizziness and headache. Another patient on placebo abandoned the study at week 4 for unknown reasons. None of the laboratory changes were serious or of clinical relevance, except for the patient with a gout attack. This patient had an unknown history of hyperuricemia unrelated to the drug. No orthostatic hypotension was documented or spontaneously reported by the patients among the groups.
Discussion
The present study compared the efficacy of three therapeutic modalities -fosinopril or hydrochlorothiazide as monotherapy and both drugs in combinationwith placebo for the treatment of patients with mild to moderate essential hypertension. Combining an ACE 
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inhibitor with hydrochlorothiazide has become a common clinical practice. Hydrochlorothiazide has been widely studied in combination with captopril, the first orally active ACE inhibitor. 8 The rationale supporting this combination is the recognized additive effect of the thiazide, particularly hypokalemia. 6 
"
8 Also, when antihypertensive agents with different mechanisms of action are given in combination, the effective therapeutic dose of each is smaller than the effective dose of each agent given alone; these lower doses minimize the potential for dose-dependent adverse side effects. 6 Acknowledging the fact that a fixed combination of any antihypertensive therapy has limitations, such as choosing the appropriate drugs and/or their respective doses in order to effectively reduce both blood pressure and the risk factors for end-organ damage, 9 we decided to use modest doses and distinct tablets of 20 mg fosinopril and 12.5 mg hydrochlorothiazide for the combination therapy. Such balance maximizes ACE blockage, which, in our past experience using other ACE inhibitors, provided higher response rates with minimal side effects. The combination resulted in the most effective therapy, normalizing blood pressure as early as the first 2 weeks of treatment. Efficacy in the other groups in decreasing order was fosinopril monotherapy, achieving normalization at week 8, and then hydrochlorothiazide and placebo. Although the latter two therapies reduced SeDBP, they did not normalize it.
Our overall results suggest that some patients in all treatment groups may require higher doses of the administered therapy to achieve normalization of SeDBP. However, this was the case in the minority of patients taking either fosinopril alone or in combination with hydrochlorothiazide. Based on the present findings, it is advisable to maintain each patient with the effective therapeutic modality and minimal dose that normalizes blood pressure. However, it is expected that normalization will increase with combination therapy when monotherapy fails. Further studies to confirm this therapeutic approach are warranted.
The number of adverse events was similar or fewer compared with the number reported in the placebo group, which had the highest. This can be explained by the modest doses used for hydrochlorothiazide and the recognized low incidence of side effects of ACE inhibitors when used alone or with a diuretic. 68 It is well known that the combination of two antihypertensive agents with different mechanisms of action allow the reduction of the effective therapeutic dose of each individual agent and, consequently, the risk of associated side effects. Laboratory changes attributed to the different therapies had no clinical implications.
The relatively high placebo response observed in this group could be attributed to a shorter duration of hypertension compared with the other groups. Although the numerical difference is clear, it was not statistically significant, possibly because of the small number of patients. 10 The difference also may have been caused by the psychosocial approach and/or the associated placebo effect of the trial itself.
11
Fosinopril (20 mg/d) used alone or in combination with hydrochlorothiazide (12.5 mg) resulted in a safe and more effective therapy than hydrochlorothiazide alone or placebo in the treatment of mild to moderate essential hypertensive patients. When a low dose of an antihypertensive monotherapy is not effective, combination therapy can be considered. This therapeutic modality can be given in separate tablets; however, if both drugs are given in a single-tablet formulation, this may facilitate its administration and patients' compliance.
